Simultaneous semimechanistic population analyses of levofloxacin in plasma, lung, and prostate to describe the influence of efflux transporters on drug distribution following intravenous and intratracheal administration

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 946-954

  Zimmermann, Estevan Sonego ^a   Laureano, João Victor ^a   Dos Santos, Camila Neris ^a   Schmidt, Stephan ^b   Lagishetty, Chakradhar V ^b   De Castro, Whocely Victor ^c   Dalla Costa, Teresa ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF FLORIDA   (United States)

^c FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; MULTIDRUG RESISTANCE PROTEIN; TARIQUIDAR; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUBULE EXCRETION; LUNG PARENCHYMA; MALE; MICRODIALYSIS; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE; RAT; ANIMAL; BLOOD; CALIBRATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; LUNG; METABOLISM; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTI-BACTERIAL AGENTS; CALIBRATION; DRUG ADMINISTRATION ROUTES; LEVOFLOXACIN; LUNG; MALE; MICRODIALYSIS; P-GLYCOPROTEIN; PROSTATE; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84957928139     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02317-15     Document Type: Article

References (42)

1. World Health Organization (WHO). 2014. Antimicrobial resistance. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs194/en. Accessed 20 Feb 2015.
2. Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, Klugman KP, Courvalin P. 2002. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis 35:721-727. http://dx.doi.org/10.1086/341900.
3. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. 2014. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 22:438-445. http://dx.doi.org/10.1016/j.tim.2014.04.007.
4. Theuretzbacher U. 2007. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 7:498-504. http://dx.doi.org/10.1016/j.coph.2007.05.003.
5. Gonzalez D, Schmidt S, Derendorf H. 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev 26:274-288. http://dx.doi.org/10.1128/CMR.00092-12.
6. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29. http://dx.doi.org/10.1016/S0169-409X(02)00169-2.
7. Leslie EM, Deeley RG, Coleb SP. 2005. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237. http://dx.doi.org/10.1016/j.taap.2004.10.012.
8. Staud F, Ceckova M, Micuda S, Pavek P. 2010. Expression and function of P-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 596:199-222. http://dx.doi.org/10.1007/978-1-60761-416-6-10.
9. Food and Drug Administration (FDA). 2008. Initial U.S. approval, 1996. Levaquin® full prescribing information. FDA, Rockville, MD. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021721s020-020635s57-020634s52-lbl.pdf. Accessed 20 Feb 2015.
10. Bolon MK. 2011. The newer fluoroquinolones. Med Clin North Am 95: 793-817. http://dx.doi.org/10.1016/j.mcna.2011.03.006.
11. Fish DN, Chow AT. 1997. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119. http://dx.doi.org/10.2165/00003088-199732020-00002.
12. Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, Boccumini L, Weisinger B, Corrado M, Kahn J. 2000. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 44:2046-2051. http://dx.doi.org/10.1128/AAC.44.8.2046-2051.2000.
13. Bulitta JB, Kinzig M, Naber CK, Wagenlehner FME, Sauber C, Landersdorfer CB, Soergel F, Naber KG. 2011. Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. Chemotherapy 57:402-416. http://dx.doi.org/10.1159/000329520.
14. Lee LJ, Sha X, Gotfried MH, Howard JR, Dix RK, Fish DN. 1998. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 18:35-41. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03824.x.
15. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J Antimicrob Chemother 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
16. Hutschala D, Skhirtladze K, Zuckermann A, Wisser W, Jaksch P, Mayer-Helm BX, Burgmann H, Wolner E, Müller M, Tschernko EM. 2005. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chemother 49:5107-5111. http://dx.doi.org/10.1128/AAC.49.12.5107-5111.2005.
17. Hurtado FK, Weber B, Derendorf H, Hochhaus G, Dalla Costa T. 2014.Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. Antimicrob Agents Chemother 58:678-686. http://dx.doi.org/10.1128/AAC.01884-13.
18. Endres CJ, Hsiao P, Chung FS, Unadkat JD. 2006. The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517. http://dx.doi.org/10.1016/j.ejps.2005.11.002.
19. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. 1987.Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84:265-269. http://dx.doi.org/10.1073/pnas.84.1.265.
20. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissue. J Histochem Cytochem 38:1277-1287. http://dx.doi.org/10.1177/38.9.1974900.
21. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P. 2001. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758.
22. Brillault J, De Castro WV, Couet W. 2010 Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother 54:543-545. http://dx.doi.org/10.1128/AAC.00733-09.
23. Brunner M, Derendorf H, Müller M. 2005. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol 5:495-499. http://dx.doi.org/10.1016/j.coph.2005.04.010.
24. Chaurasia CS, Müller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL, Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. 2007. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24:1014-1025. http://dx.doi.org/10.1007/s11095-006-9206-z.
25. de Araujo BV, da Silva CF, Haas SE, Dalla Costa T. 2009. Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp. infected Wistar rats. Int J Antimicrob Agents 33:154-159. http://dx.doi.org/10.1016/j.ijantimicag.2008.08.020.
26. Azeredo FJ, de Araujo BV, Haas SE, Torres B, Pigatto M, de Andrade C, Dalla Costa T. 2012. Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. Antimicrob Agents Chemother 56:5852-5857. http://dx.doi.org/10.1128/AAC.01323-12.
27. Freddo RJ, Dalla Costa T. 2002. Determination of norfloxacin free interstitial levels in skeletal muscle by microdialysis. J Pharm Sci 91:2433-2440. http://dx.doi.org/10.1002/jps.10230.
28. Tasso L, Bettoni CC, Oliveira LK, Dalla Costa T. 2008. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. Int J Pharm 358:96-101. http://dx.doi.org/10.1016/j.ijpharm.2008.02.023.
29. FDA. 2013. Food and Drug Administration guidance for industry: bioanalytical method validation. U.S. Food and Drug Administration, Washington, DC.
30. Konety BR, Somogyi G, Atan A, Muindi J, Chancellor MB, Getzenberg RH. 2002. Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D3 (calcitriol) using a microdialysis technique. Urology 59:947-952. http://dx.doi.org/10.1016/S0090-4295(01)01652-1.
31. Shargel L, Wu-Pong S, Yu ABC. 2012. Applied biopharmaceutics and pharmacokinetics, 6th ed. McGraw-Hill, New York, NY.
32. Tronde A, Nordén B, Marchner H, Wendel AK, Lennernäs H, Bengtsson UH. 2003. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 92:1216-1233. http://dx.doi.org/10.1002/jps.10386.
33. Marchand S, Frasca D, Dahyot-Fizelier C, Breheret C, Mimoz O, Couet W. 2008. Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state. Antimicrob Agents Chemother 52:3074-3077. http://dx.doi.org/10.1128/AAC.00242-08.
34. Johansen MJ, Newman RA, Madden T. 1997. The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 17:464-481. http://dx.doi.org/10.1002/j.1875-9114.1997.tb03057.x.
35. de Lange ECM, de Boer AG, Breimer DD. 2000. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125-148. http://dx.doi.org/10.1016/s0169-409x(00)00107-1.
36. Alvarez AI, Pérez M, Prieto JG, Molina AJ, Real R, Merino G. 2008. Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 97:3483-3493. http://dx.doi.org/10.1002/jps.21233.
37. Brillault J, De Castro WV, Harnois T, Kitzis A, Olivier JC, Couet W. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother 53:1457-1462. http://dx.doi.org/10.1128/AAC.01253-08.
38. Zeitlinger M, Müller M, Joukhadar C. 2005. Lung microdialysis - a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J 7:E600-E608. http://dx.doi.org/10.1208/aapsj070362.
39. Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD. 2011. The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2). ACS Chem Neurosci 2:82-89. http://dx.doi.org/10.1021/cn100078a.
40. 11C-verapamil and PET. J Nucl Med 49:1328-1335. http://dx.doi.org/10.2967/jnumed.108.051235.
41. 18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 49:1406-1415. http://dx.doi.org/10.1016/j.neuroimage.2009.09.048.
42. 11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Med Imaging 11:1. http://dx.doi.org/10.1186/1471-2342-11-1.